| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2007;115:2418-2425.)
© 2007 American Heart Association, Inc.
Imaging |
From the Department of Cardiovascular Medicine and University of Oxford Centre for Clinical Magnetic Resonance Research, University of Oxford, Oxford, UK (S.E.P., L.E.H., M.D.R., J.M.F., J.B.S., S.N., H.W.); Advanced Imaging Research Center, Oregon Health & Science University, Portland, Ore (M.J.-H.); and Department of Public Health, University of Oxford, Oxford, UK (H.A.D.).
Correspondence to Steffen E. Petersen, MD, DPhil, University of Oxford Centre for Clinical Magnetic Resonance Research, Department of Cardiovascular Medicine, John Radcliffe Hospital, Oxford, OX3 9DU, UK. E-mail steffen.petersen{at}cardiov.ox.ac.uk
Received August 7, 2006; accepted March 2, 2007.
Background Microvascular dysfunction in hypertrophic cardiomyopathy (HCM) may create an ischemic substrate conducive to sudden death, but it remains unknown whether the extent of hypertrophy is associated with proportionally poorer perfusion reserve. Comparisons between magnitude of hypertrophy, impairment of perfusion reserve, and extent of fibrosis may offer new insights for future clinical risk stratification in HCM but require multiparametric imaging with high spatial and temporal resolution.
Methods and Results Degree of hypertrophy, myocardial blood flow at rest and during hyperemia (hMBF), and myocardial fibrosis were assessed with magnetic resonance imaging in 35 HCM patients (9 [26%] male/26 female) and 14 healthy controls (4 [29%] male/10 female), aged 18 to 78 years (mean±SD, 42±14 years) with the use of the American Heart Association left ventricular 16-segment model. Resting MBF was similar in HCM patients and controls. hMBF was lower in HCM patients (1.84±0.89 mL/min per gram) than in healthy controls (3.42±1.76 mL/min per gram, with a difference of 0.95±0.30 [SE] mL/min per gram; P<0.001) after adjustment for multiple variables, including end-diastolic segmental wall thickness (P<0.001). In HCM patients, hMBF decreased with increasing end-diastolic wall thickness (P<0.005) and preferentially in the endocardial layer. The frequency of endocardial hMBF falling below epicardial hMBF rose with wall thickness (P=0.045), as did the incidence of fibrosis (P<0.001).
Conclusions In HCM the vasodilator response is reduced, particularly in the endocardium, and in proportion to the magnitude of hypertrophy. Microvascular dysfunction and subsequent ischemia may be important components of the risk attributable to HCM.
Related Article:
This article has been cited by other articles:
![]() |
T. D. Karamitsos, J. M. Francis, S. Myerson, J. B. Selvanayagam, and S. Neubauer The Role of Cardiovascular Magnetic Resonance Imaging in Heart Failure J. Am. Coll. Cardiol., October 6, 2009; 54(15): 1407 - 1424. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Maron, I. Olivotto, B. J. Maron, S. K. Prasad, F. Cecchi, J. E. Udelson, and P. G. Camici The case for myocardial ischemia in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol., August 25, 2009; 54(9): 866 - 875. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. H. Kwon, N. G. Smedira, E. R. Rodriguez, C. Tan, R. Setser, M. Thamilarasan, B. W. Lytle, H. M. Lever, and M. Y. Desai Cardiac magnetic resonance detection of myocardial scarring in hypertrophic cardiomyopathy: correlation with histopathology and prevalence of ventricular tachycardia. J. Am. Coll. Cardiol., July 14, 2009; 54(3): 242 - 249. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. G. Camici and O. E. Rimoldi The Clinical Value of Myocardial Blood Flow Measurement J. Nucl. Med., July 1, 2009; 50(7): 1076 - 1087. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. C. Lee and N. P. Johnson Quantification of Absolute Myocardial Blood Flow by Magnetic Resonance Perfusion Imaging J. Am. Coll. Cardiol. Img., June 1, 2009; 2(6): 761 - 770. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Grace Implantable defibrillators in hypertrophic cardiomyopathy Heart, May 1, 2009; 95(9): 695 - 696. [Full Text] [PDF] |
||||
![]() |
F Alpendurada, J Wong, and D J Pennell Practical applications of cardiovascular magnetic resonance Heart Asia, March 31, 2009; 2009(3): 16 - 22. [Abstract] [Full Text] [PDF] |
||||
![]() |
A Esposito, F De Cobelli, G Perseghin, M Pieroni, E Belloni, R Mellone, T Canu, F Gentinetta, P Scifo, C Chimenti, et al. Impaired left ventricular energy metabolism in patients with hypertrophic cardiomyopathy is related to the extension of fibrosis at delayed gadolinium-enhanced magnetic resonance imaging Heart, February 1, 2009; 95(3): 228 - 233. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Rudolph, H. Abdel-Aty, S. Bohl, P. Boye, A. Zagrosek, R. Dietz, and J. Schulz-Menger Noninvasive detection of fibrosis applying contrast-enhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy relation to remodeling. J. Am. Coll. Cardiol., January 20, 2009; 53(3): 284 - 291. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Gibbons, P. A. Araoz, and E. E. Williamson The year in cardiac imaging. J. Am. Coll. Cardiol., January 6, 2009; 53(1): 54 - 70. [Full Text] [PDF] |
||||
![]() |
M. S. Maron, J. J. Finley, J. M. Bos, T. H. Hauser, W. J. Manning, T. S. Haas, J. R. Lesser, J. E. Udelson, M. J. Ackerman, and B. J. Maron Prevalence, Clinical Significance, and Natural History of Left Ventricular Apical Aneurysms in Hypertrophic Cardiomyopathy Circulation, October 7, 2008; 118(15): 1541 - 1549. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Ashrafian and H. Watkins Exercise-induced ventricular dysfunction in hypertrophic cardiomyopathy: stunning by any other name? Heart, October 1, 2008; 94(10): 1251 - 1253. [Full Text] [PDF] |
||||
![]() |
M. Jerosch-Herold, D. C. Sheridan, J. D. Kushner, D. Nauman, D. Burgess, D. Dutton, R. Alharethi, D. Li, and R. E. Hershberger Cardiac magnetic resonance imaging of myocardial contrast uptake and blood flow in patients affected with idiopathic or familial dilated cardiomyopathy Am J Physiol Heart Circ Physiol, September 1, 2008; 295(3): H1234 - H1242. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Reichek and D. Gupta Hypertrophic Cardiomyopathy: Cardiac Magnetic Resonance Imaging Changes the Paradigm J. Am. Coll. Cardiol., August 12, 2008; 52(7): 567 - 568. [Full Text] [PDF] |
||||
![]() |
B. Sotgia, R. Sciagra, I. Olivotto, G. Casolo, L. Rega, I. Betti, A. Pupi, P. G. Camici, and F. Cecchi Spatial Relationship Between Coronary Microvascular Dysfunction and Delayed Contrast Enhancement in Patients with Hypertrophic Cardiomyopathy J. Nucl. Med., July 1, 2008; 49(7): 1090 - 1096. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. S.H. Cheng, J. B. Selvanayagam, M. Jerosch-Herold, W. J. van Gaal, T. D. Karamitsos, S. Neubauer, and A. P. Banning Percutaneous treatment of chronic total coronary occlusions improves regional hyperemic myocardial blood flow and contractility insights from quantitative cardiovascular magnetic resonance imaging. J. Am. Coll. Cardiol. Intv., February 1, 2008; 1(1): 44 - 53. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Knaapen, T. Germans, P. G. Camici, O. E. Rimoldi, F. J. ten Cate, J. M. ten Berg, P. A. Dijkmans, R. Boellaard, W. G. van Dockum, M. J. W. Gotte, et al. Determinants of coronary microvascular dysfunction in symptomatic hypertrophic cardiomyopathy Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H986 - H993. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. D. Karamitsos, J. R. Arnold, S. Neubauer, and S. E. Petersen Redefining cardiomyopathies: the role of cardiovascular magnetic resonance imaging Eur. Heart J., December 2, 2007; 28(24): 3094 - 3095. [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2007 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |